Literature DB >> 32151544

[Radiotherapy for ovarian carcinoma management: Literature review].

S Yossi1, D Nguyen2, M Khodri2, J Reure2, M Cervellera2, F Lamberth2, V Marchand2, V Mammar2, F Renoult2, E Louet2, R Coquard2, N Barbet2, F Lorchel2.   

Abstract

Ovarian cancer is the fifth most common cancer in women in France with 4714 new cases in 2017. More than 70% of patients whose disease is initially locally advanced will present locoregional or distant recurrence. Therapeutic options in this situation are not consensual. They are based on chemotherapy possibly associated with an iterative cytoreductive surgery when it is bearable by the patient. The place of radiotherapy in the management of the disease is hidden in the vast majority of national or international standards. We conducted a general review of the literature to clarify the role of irradiation in the global management of ovarian cancers, particularly in recurrence.
Copyright © 2020 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Cancer ovarien; Ovaire; Ovarian cancer; Ovary; Radiotherapy; Radiothérapie; Recurrence; Récidive; Stereotactic; Stéréotaxie

Year:  2020        PMID: 32151544     DOI: 10.1016/j.canrad.2019.10.006

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  2 in total

1.  Clinical application of radiotherapy in patients with oligometastatic ovarian cancer: a sharp tool to prolong the interval of systemic treatment.

Authors:  Jing Shen; Yinjie Tao; Lei He; Hui Guan; Hongnan Zhen; Zhikai Liu; Fuquan Zhang
Journal:  Discov Oncol       Date:  2022-08-25

2.  Abdominopelvic Lymphatic Drainage Area Irradiation for Consolidative Radiotherapy of Advanced Ovarian Carcinoma: Analysis of Clinical Application Efficacy and Dosimetric Verification.

Authors:  Jing Shen; Yin Jie Tao; Hui Guan; Hong Nan Zhen; Ting Ting Dong; Zhi Kai Liu; Fu Quan Zhang
Journal:  World J Oncol       Date:  2022-06-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.